Mersinol (Escitalopram)

Escitalopram selectively blocks the serotonin transporter on presynaptic neurons, preventing reuptake of serotonin into the nerve terminal. This raises serotonin levels in the synaptic cleft, enhancing neurotransmission in pathways that regulate mood, anxiety, and stress responses, which contributes to its therapeutic effects.

The appropriate dose of Mersinol is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and tolerability. Dosage adjustments are made according to clinical guidelines and patient-specific factors; patients should follow the prescriber’s instructions precisely.

Escitalopram is classified as Pregnancy Category B, indicating no evidence of risk in animal studies but insufficient human data. Use during pregnancy or lactation should only occur if the potential benefit justifies any potential risk, and decisions are made in consultation with a healthcare professional.

To request Mersinol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Escitalopram is a highly selective SSRI, offering a favorable side‑effect profile compared with older antidepressants such as tricyclics or monoamine oxidase inhibitors. Its potency often allows lower dosing, and it is generally better tolerated, though individual response and safety considerations remain important.

Mersinol should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture, heat and direct sunlight, and ensure the packaging remains sealed until use.

Mersinol is taken orally, usually once daily with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and not alter the regimen without medical advice.

Serious risks include serotonin syndrome, which can present with agitation, fever, and muscle rigidity, and the emergence of suicidal thoughts, especially during early treatment. Rarely, severe allergic reactions or cardiac QT prolongation may occur. Prompt medical attention is required if any of these symptoms arise.

Mersinol is contraindicated in patients with known hypersensitivity to escitalopram or any SSRI component, and in those currently taking monoamine oxidase inhibitors. Caution is also advised for individuals with a history of bipolar disorder, uncontrolled narrow‑angle glaucoma, or significant cardiac conduction abnormalities.